Conversations around persistent AF hybrid therapies: 1 Topic, 2 Continents, 3 Voices







  • Views:

    Views Icon 10735
  • Likes:

    Heart Icon 2


The U.S. Food and Drug Administration (FDA) has recently approved the EPi-Sense® System to treat patients diagnosed with long-standing persistent atrial fibrillation (AF). 

This is the only FDA approval of its kind—minimally invasive ablation therapy—patients with long-standing persistent atrial fibrillation (AF).

It significantly expands AF treatment options for this category of AF patients. With this therapy, the superiority trial showed a 35% difference in effectiveness at 18 months compared to endocardial RF ablation alone.

Incorporating both endocardial RF and epicardial therapies, the Hybrid AF Convergent procedure targets two areas where AF originates and creates transmural lesions that stop the onset of AF. This therapy may provide a long-term solution for appropriately selected patients with long-standing persistent AF.

This content was presented at EHRA 2021.

Moderated By:

A John Camm

A John Camm

Hugh Calkins

Hugh Calkins

Claudio Tondo

Claudio Tondo

This webinar is supported by:

Learning Objectives

  • Unmet treatment need in patients with advanced atrial fibrillation
  • Importance of non-pulmonary vein triggers
  • Evolution of Hybrid Convergent Therapy
  • Discussion on the future of hybrid approaches

Target Audience

  • Electrophysiologists
  • Cardiologists
  • Cardiothoracic Surgeons

Faculty Biographies

A John Camm

A John Camm

John Camm is British Heart Foundation Professor of Clinical Cardiology (Emeritus) at St George’s University of London, London, UK. His interests include cardiac arrhythmias, atrial fibrillation, stroke prevention, and anticoagulation.

Prof Camm is Editor of the European Society of Cardiology Textbook of Cardiovascular Medicine and ESC CardioMed, Electrophysiology of the Heart, Clinical Cardiology and Evidence Based Cardiology.  He has written or edited more than 40 books, predominantly in the field of cardiac arrhythmology. He has authored or co-authored more than 1450 peer reviewed papers, more than 500 book chapters, and in excess of 2500 accepted abstracts.  He has delivered more than 1000 international lectures.

Prof Camm has been involved in the production of numerous guidelines, including the ESC guidelines for the management of atrial fibrillation.

Prof Camm is a member of the Arrhythmia & Electrophysiology Review editorial board.

View full profile
Hugh Calkins

Hugh Calkins

Dr Hugh Calkins is Professor of Medicine and Director of Electrophysiology at the Johns Hopkins Medical Institution in Baltimore, USA.  

He has clinical and research interests in the treatment of cardiac arrhythmias with catheter ablation, the role of device therapy for treating ventricular arrhythmias, the evaluation and management of syncope and the study of arrhythmogenic right ventricular dysplasia.

He has certifications from the American Board of Internal Medicine in Cardiovascular Disease (1989), Clinical Cardiac Electrophysiology (1992) and Internal Medicine (1986).2

Dr Calkins has over 38 years of experience in the medical field. He is an Associate Editor of the Journal of Cardiovascular Electrophysiology and is on the editorial board of several prestigious publications including The Journal of the American College of Cardiology; HeartRhythm and Circulation: Arrhythmia and Electrophysiology. He is a former member of the American Board of Internal Medicine Electrophysiology Boards Test Writing Committee. Dr Calkins is a fellow of the American College of Cardiology, the American Heart Association and the Heart Rhythm Society. He led a 44-member international task force whose 2012 Expert Consensus Statement gave recommendations for treatment and research of atrial fibrillation. Dr Calkins is also a past president of the Heart Rhythm Society and was elected to be a member of the Miler Coulsen Academy of Clinical Excellence in 2014.

Over two decades ago Dr Calkins founded the Johns Hopkins ARVC Program, which is the largest and most comprehensive clinical and ARVC research program in the world. He is currently leading several research studies in the field on the topics of the role of exercise in ARVC, assessing the risk of sudden death in patients and the relationship between specific genetic mutations and some clinical features of the disease.

He has published more than 500 articles and book chapters on a wide variety of cardiac arrhythmias. His research has focused predominantly on catheter ablation, atrial fibrillation, syncope and arrhythmogenic right ventricular dysplasia.

Areas of Speciality

  • Adult Congenital Heart Disease
  • Cardiac Electrophysiology
  • Interventional Cardiology
View full profile
Claudio Tondo

Claudio Tondo

Dr Claudio Tondo is the chairman of the Heart Rhythm centre at Centro Cardiologico, University of Milan, Italy. Dr Tondo's interests range from clinical aspects of arrhythmias to genetics.

View full profile